Editor’s introduction to the initial issue of the ninth volume of GaBI Journal

Author(s): Professor Philip D Walson, MD

The current coronavirus pandemic raises some important questions relevant to generic and/or biosimilar products. While still unproven, there are some indications that approved antiviral compounds exist which might be able to decrease coronavirus associated morbidity and mortality. It is also possible that antibody products could be effective. It is not clear however whether/how governments will […]

Read more →